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Foreword
Thalassaemias are the most common monogenetic inherited disorders
of haemoglobin (Hb). The inheritance of thalassaemias is autosomal
recessive. Thalassaemias are globally prevalent, although prevalence
varies widely between countries of the same region, and even within
countries. Originally restricted to specific geographical locations,
thalassaemias are now global due to population migration. αthalassaemia is more frequent in the WHO South-East Asia Region
than in other parts of the world. Up to 40% of genetic traits have been
found in thalassaemia traits (1–30%). People living in the
Mediterranean, African and South-East Asian regions are more likely
to be affected by β-thalassaemia. Genetic prevalence of β-thalassaemia in the South-East
Asia Region is 2.5–15%
To provide life-long treatment to people with thalassaemia, and prevent serious complications
and premature deaths, high-quality public health planning and policy making is required, for
which high-quality epidemiological data is a must. In all countries of the Region, plans of action
to manage and control Hb disorders are needed, covering community awareness and
education, training of health care professionals, and infrastructure development to strengthen
diagnostic and transfusion services. A holistic and cost-effective approach that includes family
and population screening, a registry for epidemiological data, and a preventive programme
that includes genetic counselling, prenatal diagnosis and preimplantation genetic diagnosis,
has proven to be successful in reducing the frequency of thalassaemias in many countries
globally.
To facilitate the development of such plans, this review aims to understand the prevalence of
thalassaemic syndromes and the existent blood supply system available within each country
of the Region. The review focuses on thalassaemic syndromes, since these disorders present
mainly with transfusion-dependent anaemia and the need for periodic transfusions. The review
will help health authorities plan for and provide adequate blood supplies for each patient with
transfusion-dependent thalassaemia. The review was performed using data from
thalassaemia societies, the nodal authorities dealing with blood product support, data
published in the literature and data from WHO.
I encourage all stakeholders to leverage the information contained herein to develop national
action plans to address thalassaemias, and to continue to increase access to sufficient and
secure blood and blood products, and safe transfusion services, as a vital part of achieving
universal health coverage. Together, in all countries of the Region, we must improve access
to safe blood based on voluntary non-remunerated donations, for a fairer, healthier future for
all.

Dr Poonam Khetrapal Singh
Regional Director
WHO South-East Asia Region
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Executive summary
Disorders of haemoglobin, which affect the structure or function of haemoglobin, are
one of the most common monogenic disorders prevalent across the world. While sickle
cell disorders are more prevalent worldwide, the thalassaemic syndromes including αthalassaemia, β-thalassaemia and haemoglobin-E disease are associated with high
prevalence rates ranging from 2.5% to 15% in the 11 countries of the World Health
Organization (WHO) South East-Asia (SEA) Region. The clinical presentation can vary
from mild anaemia to severe transfusion-dependent anaemia and therefore poses
considerable strain on health-care resources and blood supplies.

In this review, we have attempted to understand the prevalence of the thalassaemic
syndromes and the existent blood supply system available within each country of the
SEA Region. This review focuses on the thalassaemic syndromes since these
disorders present mainly with transfusion-dependent anaemia and the need for
periodic transfusions unlike sickle cell anaemia where the main manifestation is
usually a painful crisis. This review will help health authorities in planning for adequate
blood supplies for each patient with transfusion-dependent thalassaemia. This review
was done using data from the thalassaemia societies from each country, the nodal
authorities dealing with blood product support within each country, data published in
the literature and data from WHO.
It is noted that within the countries of the SEA Region, there was a wide heterogeneity
in the clinical and mutational spectrum of the thalassaemic syndromes. While the risk
of β-thalassaemia major was high in India, Indonesia and Maldives followed by
Bangladesh and Thailand, HbE-β-thalassaemia was as common as β-thalassaemia in
India and Indonesia but much higher than β-thalassaemia in Bangladesh, Myanmar
and Thailand. The risk of homozygous α0-thalassaemia and HbH disease (inheritance
of only one out of the four normal alpha-globin genes [-α/--]) was highest in Thailand
followed by Myanmar. The annual number of births with β-thalassaemia were highest
in India (12 500 per 1391.99 million or 1.3 billion) followed by Bangladesh (9100 per
166.3 million or 0.1663 billion) while Thailand (4000 per 69 958 669 million), Myanmar
(2500 per 54 409 800 million) and Nepal (120 per 29 136 808 million) reported more
births with HbE-β-thalassaemia.
ix

The availability of blood as a resource also varied considerably between the various
countries of the SEA Region with the red blood cell units available per 100 000
population ranging from 3315 (Thailand) to 256 (Timor-Leste). Only four countries –
Indonesia, Maldives, Sri Lanka and Thailand – have more than 1000 red cells units
available per 100 000 population annually. It is seen that the countries that have a high
number of annual births with thalassaemia such as India, Bangladesh and Myanmar
have a lower number of red cells available for the population. In countries such as
Maldives and Nepal, geographical constraints (either waterways or mountainous
regions) play a key role in accessing blood transfusions. The under-5 mortality rates
are a good indicator of health services being provided since several children with
transfusion-dependent thalassaemia also belong to this age group. These rates are
less than 10 per 1000 live births in Maldives, Sri Lanka and Thailand and more than
20 per 1000 live births in several other countries (Bangladesh, Bhutan, India,
Indonesia, Myanmar, Nepal and Timor-Leste). While transfusion-dependent
thalassaemia is not the sole contributor to the high under-5 mortality rates in some of
the countries, it indeed plays a considerable part in contributing to these rates and,
therefore, improving blood availability to these children should be useful in reducing
these mortality rates.

A multipronged approach is needed in these countries to try and reduce the burden of
thalassaemic syndromes through counselling and prenatal diagnosis, if feasible, and
at the same time ensuring that the children who are already affected by this disease
are taken care of adequately by ensuring timely and safe blood supplies. It is
necessary to sensitize the government in each country to recognize transfusiondependent thalassaemia as a major health problem so that adequate steps can be
taken by these governments with support of WHO to improve health outcomes in
children in this Region.
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Introduction
Haemoglobinopathies are hereditary disorders affecting the structure, function or
production of haemoglobin (Hb) and are among the commonest of clinically significant
monogenic disorders (1). These are classified into two major groups: (i) thalassaemia
syndromes consisting of α‑ and β‑thalassaemia and (ii) structural variants of Hb
(abnormal Hb) including sickle cell disease (HbS), haemoglobin E disease (HbE),
haemoglobin C disease (HbC) and haemoglobin Constant Spring disease (Hb CS).
The prevalence of carriers of variants of the haemoglobin gene is very high among the
populations of the African, South-East Asian, Eastern Mediterranean and the Western
Pacific regions and much lower among the populations of the American and European
regions (2). These disorders are common in 71% of countries that collectively account
for 89% of all births and have a major impact on health-care needs of the affected
countries. HbS accounts for 40% of carriers while about 20% of the world’s population
carries a gene for α-thalassaemia. In some geographical areas, one can see a
combination of a thalassaemia syndrome and a structural variant of Hb, the
commonest type being HbE-β-thalassaemia with similar clinical presentations. It is
therefore necessary to study the geographical distribution of severe illness since these
diseases present a major health-care burden for the country.

The clinical spectrum of these Hb disorders can range from a silent carrier status to
mild non-transfusion-dependent (NDT) anaemia to severe transfusion-dependent
anaemia. Since anaemia is the predominant symptom, the major treatment consists
of regular transfusions of red blood cells throughout life. The transfusion practice can
range from transfusions every 2–4 weeks to once every 2–3 months depending upon
the clinical severity of the disease. Blood transfusion corrects anaemia and promotes
normal growth. Since blood transfusion is a key component of the clinical management
of transfusion-dependent thalassaemia (TDT), it is essential that blood transfusion
services in all the countries are strengthened to ensure the availability of a safe and
adequate blood supply for all patients who need regular transfusions.
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Haemoglobin disorders with focus on thalassaemia
The thalassaemia syndromes form one of the major groups of haemoglobinopathies.
They are a group of monogenic disorders in which a genetic mutation interferes with
the amount of protein that is produced and includes both α‑ and β‑thalassaemia.
In a physiological state, the Hb molecule is a heterotetramer consisting of two α- and
two non-α-globin chains, each carrying a haeme molecule with a central iron. The
oxygen-carrying capacity of the Hb molecule is maximal in this state. The non-α-globin
chains can either be β chains which coupled with α chains form adult Hb (HbA), while
α chains and δ chains form a minor fraction of adult Hb (HbA2). Finally, α and γ chains
form the fetal haemoglobin (HbF). The production of the globin chains is regulated by
the α-globin cluster on chromosome 16 with the two α-globin genes HBA1 and HBA2,
and the β-globin cluster on chromosome 11 with the genes for the γ, δ and β-globin
chains. In a normal physiological state, there is a balanced production of the α- and
the non-α-globin chains that ensures a reciprocal pairing into the normal tetramers. In
the thalassaemias, this equilibrium is disrupted by the defective production of one of
the globin chains. Any reduced production of one of the globin chains within the
developing red cell will cause an accumulation of the normally produced chain that
can no longer find the equivalent amount of its heterologous partner to assemble to
the normal heterotetramer. If α-globin chains are not produced in adequate amounts,
there will be an accumulation of β-globin chains (α-thalassaemia); alternatively, if βglobin chains are inadequately produced, then α-globin chains will accumulate (βthalassaemia). The α-thalassaemias occur mainly due to deletions – a deletion of one
of the globin genes is termed α+-thalassaemia, whereas if both the pairs are deleted
it is termed α0-thalassaemia. Point mutations of the α genes are much less common;
only one, Hb CS occurs at a very high frequency in some populations. The βthalassaemias however result from more than 200 different mutations, and deletions
are much less common.
In the premature red cells (erythroblasts), the presence of excess of α-globin chains
in β-thalassaemia causes precipitation at the cell membrane leading to oxidative
membrane damage and premature cell death by apoptosis (3). This happens within
the tissue that promotes red cell formation and thus results in ineffective
erythropoiesis. Some of the immature red cells however pass into the circulation and
because of their membrane defect, they are fragile and prone to haemolysis. They
2

also exhibit an altered deformability and are trapped by the spleen where they are
destroyed by macrophages. This leads to an enlargement of the spleen, which can
become massive, leading to the development of functional hypersplenism with
removal of platelets and white cells as well as red cells.
The presence of ineffective erythropoiesis, the removal of abnormal cells by the
spleen, and haemolysis all contribute to the anaemia of variable severity that is seen
in β-thalassaemia (4).
β-thalassaemia can be classified into three groups based upon the clinical severity:
1.

Transfusion-dependent β-thalassaemia (TDT) – leads to death in early infancy
unless treated.

2.

Non-transfusion-dependent β-thalassaemia (NDT) – occasional blood
transfusions required but may become transfusion-dependent later in life.

3.

Thalassaemia minor – mostly consist of carriers for thalassaemia genes but
may also include some homozygotes/compound heterozygotes for mild βthalassaemia mutations and HbE.

There can also be co-inheritance of different mutations involving the β-thalassaemia
gene and the gene involving the structural variants leading to the genotypic and
phenotypic manifestations as HbS-β-thalassaemia (sickle-β-thalassaemia) or HbE-βthalassaemia (E-β-thalassaemia). The hallmark of thalassaemia major is severe
anaemia that usually becomes apparent at 3–6 months after birth when the switch
from fetal Hb (HbF) (α2γ2) to adult Hb (HbA) (α2β2) production should take place.
Typically, the infant presents in the first year of life with severe pallor, failure to thrive
and abdominal distension due to splenomegaly. Because of the ineffective
erythropoiesis due to the genetic defect, there is repeated drop in Hb and this
continuous fall leads to the need for repeated blood transfusions. Since anaemia is
the predominant symptom in thalassaemia major, the treatment essentially consists of
regular transfusions of red blood cells throughout life (5). Transfusion is usually
administered every 2–4 weeks with the aim of maintaining a pre-transfusion Hb level
of 9–10.5 g/dL. The strategy of repeated blood transfusion not only helps in the
correction of anaemia but is also required for promotion of normal growth and
prevention of physical abnormalities and to suppress bone marrow hyperactivity that
is responsible for the characteristic skeletal changes seen with thalassaemia. Regular
3

lifelong transfusions however are associated with several possible adverse effects,
which include immunological reactions, development of antibodies to red cell antigens
and transmission of infectious agents (hepatitis B and hepatitis C). Since blood
transfusion is one of the first and most critical components of the clinical management
of TDT, it is imperative that blood transfusion services in each country, which have a
burden of this disease, provide an adequate blood supply that is safe. A major sideeffect, however, is the accumulation of iron from the transfused red blood cells. In
patients receiving regular transfusions, the generation of free iron leads to organelle
damage and cell death, especially in the liver, heart and endocrine glands leading to
various clinical manifestations including short stature, hypothyroidism, impaired
glucose tolerance, hypoparathyroidism and hypogonadism. The life-endangering
effects of iron toxicity need close monitoring with quantification of the iron load in the
tissues and removal of excess iron with the use of iron-chelating agents.
Global perspective
Collectively, the inherited disorders of Hb including sickle cell anaemia and its variants
and the thalassaemias are the most common genetic disorders worldwide. These
diseases occur mainly in the tropical and subtropical areas. There are several reasons
for the high gene frequency in several tropical countries (1). First and foremost, the
high gene frequency reflects natural selection through protection of carriers against
severe malaria. Another major factor is the relatively high frequency of
consanguineous marriages in many of these countries; this mechanism is known to
have a key effect on increasing the gene frequency of any recessively inherited
disorder. Epidemiological transition is another factor whereby as public health and
nutritional standards improve in poorer countries, babies with these conditions who
would otherwise have died in early life are now living long enough to present for
diagnosis and management; an example of this being Cyprus. Finally, the varying
distribution of some of the Hb disorders in different populations may reflect the strong
founder effects by their original inhabitants as seen in populations of the Pacific Island.
The α+-thalassaemias are more common worldwide compared to the β-thalassaemias
(6). The α+-thalassaemias are present across the tropical belt from sub-Saharan
Africa through the Middle East, South Asia, and South-East Asia with heterozygote
frequencies in part of North India and South-East Asia reaching 75%. The more severe
form of α-thalassaemia, α0-thalassaemia, is less common and is seen at a high
4

frequency in the Mediterranean region and in South-East Asia. The β-thalassaemias
are less common in sub-Saharan Africa and spread across the rest of the tropical belt
at varying frequencies. HbE is an extremely common structural Hb variant, occurring
in South and South-East Asia and reaching very high frequencies in parts of SouthEast Asia with 70% heterozygote rates in the HbE triangle of North Thailand and
Cambodia. It is therefore extremely common to see HbE-β-thalassaemia in this region.
Worldwide estimates show that each year, over 40 000 new patients are born with a
severe form of thalassaemia (β‑thalassaemia major and HbE-β‑thalassaemia) and
nearly 80% of these births occur in developing countries (Table 1). The distribution of
the thalassaemia genes stretches from the Mediterranean basin and sub-Saharan
Africa through the Middle East to the Far East including South China and the Pacific
Islands (Fig. 1). However, with constant migration that is occurring globally, Hb
disorders, which were originally endemic in 60% of 229 countries, potentially affecting
75% of births, are now sufficiently common in 71% of countries among 89% of births
(either in the whole population or among minorities). It is estimated that 80–90 million
people are carriers for one of these genes, which is 1–1.5% of the population.
Table 1. Estimated annual births with severe β-thalassaemia in each WHO
region (2)
WHO region

Estimated annual births with β-thalassaemia
Total

Transfusion-dependent

African

1386

1278 (92.2%)

American

341

255 (74.78%)

Eastern Mediterranean

9914

9053 (91.3%)

European

1019

920 (90.28%)

South-East Asia

20 420

9983 (48.88%)

Western Pacific

7538

4022 (53.35%)

40 618

25 511 (62.8%)

World
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Fig. 1. World map – distribution of thalassemia and sickle cell anaemia (courtesy of
Dr Sitalakshmi, St Johns, Bangalore, India)

Regional perspective
The SEA Region of WHO has 11 nations with a combined population of 2.02 billion.
The ethnic origins of people living in these countries are also very heterogeneous. The
Mon-Khmer and Thai language-speaking people occupy Thailand and some parts of
Myanmar. The Malayopolynesians (Austronesian) live in Indonesia and several Pacific
Island nations (7). The South Asian nations of Bangladesh, India and Sri Lanka are
very heterogenous and have their own specific ethnic populations. Therefore, the
entire region is very heterogeneous leading to varying degrees of Hb disorders that
are seen in these populations. β-thalassaemia is more common in the Mediterranean
region while α-thalassaemia is more common in the Far East. Therefore, as one
moves from South Asia to South-East Asia, one is likely to encounter a higher
incidence of α-thalassaemia and the structural variants of thalassaemia. In South-East
Asia, α-thalassaemia, β-thalassaemia, HbE and Hb CS are prevalent. The gene
frequencies of α-thalassaemia reach 30–40% in Northern Thailand whereas βthalassaemias vary between 1% and 9%. HbE is the hallmark of South-East Asia
6

attaining a frequency of 70% at the junction of Thailand, Laos and Cambodia. Hb CS
gene frequencies vary between 1% and 8%. These abnormal genes in different
combinations lead to over 60 different thalassaemia syndromes, making South-East
Asia an area with the most complex thalassaemia genotype. Interaction of the βthalassaemia carrier gene with the structural variants can often result in nontransfusion-dependent form of thalassaemia that is commonly known as thalassaemia
intermedia (e.g. compound heterozygous mutations involving β-thalassaemia and
HbE disease leading to E-β-thalassaemia). A detailed understanding of the frequency
distribution of these various phenotypes will help in planning transfusion strategies
since a majority of patients with thalassaemia intermedia and all with thalassaemia
trait do not require blood transfusions to sustain life while it is an essential requirement
for patients with thalassaemia major.

Blood transfusion services – global and regional perspective
Global perspective
Since patients with thalassaemia major require monthly packed red cell transfusions
to maintain their Hb at normal levels, an uninterrupted supply of blood and blood
products should be ensured for these patients. To achieve this, there should be a
robust programme of blood collection through various mechanisms for enhancing
voluntary blood donations. It is also necessary that the blood collected is tested for
transfusion-transmissible infections (TTIs) prior to transfusion.

The WHO Global Database on Blood Safety (GDBS) reported a marked variation in
blood donation in various WHO regions (Table 2) (8). Of the 118.5 million blood
donations collected globally, 40% were collected in high-income countries, home to
16% of the global population (9). About 13 300 blood centres in 169 countries reported
collecting a total of 106 million donations and these collections at various blood centres
varied according to income groups. The median annual donations per blood centre is
1300 in low-income countries, 4400 in lower middle-income countries and 9300 in
upper middle-income countries, compared to 25 700 in high-income countries. There
is a marked difference in the level of access to blood between low- and high-income
countries. The whole blood donation rate is an indicator for the general availability of
blood in a country. The median blood donation rate in high-income countries is 31.5
7

donations per 1000 people. This compares with 15.9 donations per 1000 people in
upper middle-income countries, 6.8 donations per 1000 people in lower middle-income
countries, and 5.0 donations per 1000 people in low-income countries.

Table 2. Estimated blood donation by WHO regions (2013) (8)
WHO region

Estimated whole

Estimated

Total

blood donation

apheresis

(millions)

(millions)

donations
(millions)

Africa

5.6

0.03

5.6

Americas

20.4

2.0

22.4

Eastern

9.9

0.04

9.9

Europe

26.5

6.1

32.5

South-East Asia

16.6

0.06

16.7

Western Pacific

21.6

3.7

25.3

Global

100.6

11.9

112.5

Mediterranean

(Rounded totals)

To have an adequate and reliable supply of safe blood, it is necessary to have a stable
base of repeat, voluntary, unpaid blood donors. These are also the safest group of
donors as the prevalence of bloodborne infections is lowest among this group. Though
156 countries have reported an increase of 7.8 million blood donations from voluntary
unpaid donors from 2013 to 2018, most of this increase was in the region of the
Americas (25%) and Africa (23%). Only 79 countries (mainly high- and middle-income]
are able to collect more than 90% of their blood supply from voluntary unpaid blood
donations while in 56 countries (mainly middle-income and lower-income), more than
50% of the blood supply is still dependent on family/replacement donors. A modelling
study involving 195 countries using data from the 2016 WHO Global Status Report on
Blood Safety and Availability and estimates of the global disease-specific transfusion
need suggested that in 2017, the global blood need was 304 711 244 and the global
blood supply was 272 270 243 blood product units, with a need-to-supply ratio of 1.12
(95% UI 1.07–1.16). Of the 195 countries, 119 (61%) did not have a blood supply
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sufficient to meet their needs (10). The WHO Global Status Report on Blood Safety
and Availability has reported that in high-income countries, blood transfusion is mostly
used for supportive care in cardiovascular surgery, transplant surgery, massive
trauma, and therapy for solid and haematological malignancies while in low- and
middle-income countries, it is used more often to manage perinatal haemorrhage,
severe childhood anaemia and traumatic haemorrhage.

Regional perspective
Of the 11 countries that form the WHO SEA Region, one (Democratic People’s
Republic of Korea) country belongs to the lower-income group, seven (Bangladesh,
Bhutan, India, Myanmar, Nepal, Sri Lanka, Timor-Leste) belong to the lower middleincome group while three (Indonesia, Maldives, Thailand) belong to the upper middleincome group (10). Countries of the SEA Region reported the collection of 15% of
global blood donations, though these countries represent 26% of the global population.
Countries in the low-income and lower middle-income groups collected 2% and 22%
of the global donations, respectively, though their populations represent 9% and 39%
of the global population, respectively (Table 2). While the median whole blood
donation rate was 32.1 donations per 1000 population per year in high-income
countries, it is 14.9 (range 6.7–39.7) for upper middle-income countries, 7.8 in lower
middle-income countries, and 4.6 in low-income countries. Across WHO regions, the
donation rates ranged from 1.8 to 30.8 (median 7.9) in South-East Asia. As mentioned
earlier, in several middle-income and low-income countries, more than 50% of the
blood supply is still dependent on family/replacement and not through voluntary unpaid
donors. A modelling study published in the Lancet in 2019 suggests that 119 (61%)
countries (including Bangladesh, Bhutan, India, Indonesia, Maldives, Myanmar, Nepal
and Timor-Leste but excluding Sri Lanka and Thailand) did not have a blood supply
sufficient to meet their need (10). Across these 119 countries, the unmet need totalled
102 359 632 (95% UI 3 381 710–111 360 725) blood product units, equal to 1849
(1687–2011) units per 100 000 population globally. Every country in central, eastern
and western sub-Saharan Africa, Oceania and South Asia had insufficient blood to
meet their needs.
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Bangladesh
Bangladesh is the eighth most populous country in the world. Bangladesh shares land
borders with India to the west, north and east, Myanmar to the southeast and is
narrowly separated from Nepal, Bhutan and China. A majority of the Bangladeshis
(98.5%) belong to the Bengali ethno-linguistic group with ethnic minorities accounting
for the rest. The country is divided into eight administrative divisions and 64 districts.

Burden of thalassaemia in Bangladesh
Noor et al. studied the carrier frequency of thalassaemia genes in a cohort of 1877
individuals in the age group of 18–35 years (11). The participants were from both rural
and urban origins. About 4.32% of participants had consanguineous parents; 224
participants (11.89%) carried a single gene mutation for thalassaemia. Of the 11.89%
carriers of β-globin gene mutations, 8.68% had HbE trait while 2.24% had βthalassaemia trait. The carrier frequency among the participants with a history of
consanguinity was 23.5%, whereas it was almost half (11.4%) among the children of
non-consanguineous parents. The frequency of both HbE trait and thalassaemia trait
varied across the eight divisions in Bangladesh. The frequency of HbE trait varied from
as low as 4.2% in Khulna division to as high as 25% in Rangpur division. Conversely,
the highest frequency of β-thalassaemia trait was found in Barisal division (3.9%). The
highest frequency of β-thalassaemia trait and HbE trait was found in Rangpur division
(27.1%) followed by Rajshahi division (16.4%).
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Fig. 2. Frequency of β-thalassaemia and HbE trait across the eight administrative
divisions of Bangladesh (11)

Khan et al. published data in 2005 on the prevalence of thalassaemia among (n=735)
schoolchildren in Bangladesh and showed a 4.1% prevalence of the β-thalassaemia
trait and a 6.1% prevalence for the HbE trait (14). The same study revealed the
regional variation of 2.9% to 8.1% for β-thalassaemia carriers and 2.4% to 16.5% for
HbE carriers. Among tribal children, the prevalence of β-thalassaemia trait was almost
identical but HbE was much higher (41.7%).
Between 2009 and 2014, Hossain et al. studied the patterns of thalassaemia among
patients attending care at the Thalassaemia Foundation Hospital (TFH) located in
Dhaka (12). Over the 5-year period, a total of 1594 thalassaemia patients were served
by the TFH, of which 1178 complete cases were analysed. About 77.3% of patients
were diagnosed as HbE-β-thalassaemia, while nearly 15% were β-thalassaemia
major. About 91% of patients (n=971) required blood transfusion, where 66.9% of them
were TDT patients and 24.3% were NTDT patients, thus requiring fewer transfusions
than the former group. About 41.1% of TDT patients required blood transfusion every
2–4 weeks.
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With the current HbE trait and β-thalassaemia trait carrier frequency of 10.92%, it is
estimated that 9176 babies are born with thalassaemia each year. The overall
estimates suggest 60–70 000 patients with β-thalassaemia or HbE-β-thalassaemia in
Bangladesh (12). It should be remembered that the clinical manifestations of HbE-βthalassaemia are varied. Based on clinical severity, they could be classified into three
categories: mild (15% cases), moderately severe (majority of HbE-β-thalassaemia
cases) and severe. Up to 50% of all patients with HbE-β-thalassaemia represent
clinical manifestations like those of thalassaemia major.

Blood transfusion services in Bangladesh
Blood Transfusion Services (BTS) were established in Bangladesh in 1950 at the
Dhaka Medical College Hospital and in 1976, the National Council of Blood
Transfusion was set up. Until 2000, most of the country’s blood supply was obtained
by professional donors (47%). The Safe Blood Transfusion Act was legislated in April
2002 and enforced from August 2004 as the regulatory law for blood transfusion
centres. This law also encouraged the promotion of voluntary non-remunerated blood
donation (VNRBD) through improved donor motivation and promotional campaigns. A
national blood policy was approved in November 2013. However, there is no
centralized blood collection system at the national level and no organization
specifically supports and coordinates VNRBD. In 2019, the government launched the
national guidelines on thalassaemia management for the physician.
In Bangladesh, there are 232 blood banks in the government sector and 150 in the
private sector. Overall, the major providers of blood in Bangladesh include the
government and private hospital-based blood banks (80%), Bangladesh Red Crescent
Society (11%), medical college-based voluntary organizations (5%) and private
organizations (4%). According to the Blood Transfusion Society of Bangladesh,
approximately 600 000 units of blood are required annually (13). Most of the donations
(70%) come from replacement through family relative donors while 30% come through
voluntary donors, with no paid donors. Transfusion of children with thalassaemia
occurs through organizations such as the Bangladesh Thalassaemia Foundation,
Bangladesh Thalassaemia Samiti, Bangladesh Thalassaemia Society and the daycare transfusion centre in the Bangladesh Red Crescent Blood Centre. Transfusions
also occur through individual hospitals.

12

Bhutan
Bhutan is a landlocked country in South Asia located in the Eastern Himalayas and is
bordered by Tibet in the north and the west along with various states of India in the
west, south and east. Bhutan is divided into 20 Dzongkhag (districts), administered by
a body called the Dzongkhag Tshogdu. Bhutanese people primarily consist of the
Ngalops and Sharchops, called the Western Bhutanese and Eastern Bhutanese,
respectively while the Lhotshampa, meaning "southerner Bhutanese", are a
heterogeneous group of mostly Nepalese ancestry. The Ngalops (also known as
Bhote) constitute 50% of the population while ethnic Nepali (predominantly
Lhotshampas) constitute 35% and indigenous or migrant tribes constitute 15%.

Burden of thalassaemia in Bhutan
Limited data are available on the prevalence of thalassaemia in Bhutan though a high
incidence of anaemia has been reported (30–40% among children, adolescent girls,
pregnant and non-pregnant women) (15). The reported frequency of β-thalassaemia
and HbE disease in Bhutan is less than 1% (16). A survey done by University College,
London in 2007 showed that among pregnant women, α+-thalassaemia carrier status
was 31.9% with no α0-thalassaemia carrier status along with a 0.07% incidence of βthalassaemia carrier status (2). Overall, among pregnant women who carried an
abnormal thalassaemia gene, 92% were carriers of an α-globin gene variant while
0.16% were carriers of a β-globin gene variant and 7.8% were carriers of both α- and
β-globin gene variants. In terms of the combinations of abnormal variants per 1000
conceptions, the births with haemoglobinopathies in Bhutan is very low – 0.001 with
homozygous β-thalassaemia and 0.015 with HbE-β-thalassaemia.

Blood transfusion services in Bhutan
Bhutan has a coordinated National Blood Transfusion Service (NBTS), which is
managed by the National Blood Centre (NBC) in the capital city of Thimphu. The NBC
caters to blood needs of the 380-bedded Jigme Dorji Wangchuk National Referral
Hospital where it is based and to the district hospitals in the western region of the
country. There are 27 functional hospital-based blood centres throughout the country,
which collect about 8028 units out of which voluntary donations are 3686 (46%) and
family relative donors are 4342 (54%) (17). The functions of the NBTS include
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recruitment and education of blood donors, blood donation, counselling and postdonation care, blood component production, immunohaematology and testing for
TTIs, patient blood management, quality assurance and haemovigilance.

Fig. 3. Organizational structure of the NBTS, Bhutan

There has been a steady increase in the number of blood donations and the number
of VNRBDs. A status report issued in 2017 suggested that the total number of blood
donations annually had improved from 8175 in 2011 to 9917 in 2016 and the
respective percentage of VNRBDs has improved from 56% to 77% (8).

The annual blood report of 2019 revealed a total blood collection of 10 773 units (1.4%
of the total population) (18). Of these, 9302 (86.3%) were voluntary donations while
1471 (13.7%) were replacement donors. A total of 60 blood donation camps were
organized throughout the year and 3485 units were discarded with 43% of them being
expired blood units.
The NBTS has been playing a major role since 2009 in improving transfusion practices
in Bhutan, which includes developing various national documents such as national
standards, guidelines for clinical use of blood, blood donor selection and retention
criteria. In 2017, standard operating procedures (SOPs) on safe bedside clinical
transfusion practices (CTP) were developed through a technical working group
14

involving blood service personnel, nurses, nursing tutors and representatives of the
blood safety programme. There are two qualified and dedicated transfusion medicine
specialists in the country and there are other trained doctors to run the BTS. Trained
doctors/technologists across the country manage the BTS efficiently; however, a few
challenges still remain for the BTS in Bhutan. Some of them are: the difficult
geographical terrain, to increase the number of voluntary donors, inconsistent supplies
of

test

reagents

and

consumables,

and

blood/components by clinicians and nurses.
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Democratic People’s Republic of Korea (North Korea)
DPR Korea is situated in the northeastern part of Asia constituting the northern part of
the Korean peninsula. The country is bordered to the north by China and Russia and
to the south by Republic of Korea. According to The World Factbook, North Korea is
racially homogeneous and contains a small Chinese community and a few ethnic
Japanese. The 2008 census listed two nationalities: Korean (99.998%) and Other
(0.002%). Administratively, the entire country is divided into nine provinces and two
special cities: the capital city of Pyongyang and Nampo. Provinces are divided into
cities (districts) and counties.

Burden of thalassaemia in DPR Korea
No data are available on the frequency of thalassaemia but based on data for DPR
Korea, a low frequency of carrier rate for thalassaemia is expected possibly due to the
absence of selection in favour of the β-thalassaemia genes (19). In neighbouring
South Korea, thalassaemia is not a major problem; however, there has been an
increase in prevalence due to increasing immigration (20). China is a neighbour in the
north and the overall prevalence there of α-thalassaemia, β-thalassaemia and α+-βthalassaemia was 7.88%, 2.21% and 0.48%, respectively; however, the geographical
distribution of thalassaemia was highest in the south of China and decreased from
south to north.

Blood transfusion services in DPR Korea
The Red Cross Society was initially involved in blood banking services including donor
recruitment. However, since the mid-1950s, the Ministry of Public Health (MoPH) has
taken over the responsibility. The blood banking service is nationally coordinated and
centrally managed by the government under the MoPH (21).
In 1999, WHO completed a study of the blood transfusion system in DPR Korea (22).
This study showed that nearly 25 000 volunteers donate blood every year without
remuneration at the NBC in Pyongyang, out of a total pool of 40 000 blood donors.
Despite occasional shortages, the blood supply is reported to be adequate for the
country’s demand. The study also identified challenges with the blood transfusion
system in DPR Korea. These included the following:
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1. Use of glass bottles instead of disposable blood bags, which are required to be
washed and sterilized before use
2. Use of latex tubing sets at least three times before being discarded
3. Lack of financial resources
4. Limited staff training and development
5. Inadequate physical infrastructure
6. Absence of back-up generators for domestic refrigerators in regional blood
banks and hospitals.
Since then, there have been multiple levels of support to improve the blood transfusion
system. WHO has been supporting the NBC with blood bags reaching 130 000 bags
in the previous biennium of 2018–2019, which have contributed much to the National
Blood Safety Programme to address the need for safe blood and improve health care
of the people. During a visit to the Central Blood Centre in January 2020 by the WHO
country team, the MoPH suggested their strong intention to have their own production
of blood bags to attain self-sufficiency in the country, which is approximately 150 000
pieces every year (23). A plan is in place for the NBC which will have the first plant of
its own to manufacture blood bags. The WHO country office will continue to support
the supply of blood bags to address the ongoing need for 150 000 pieces even during
2020 as it will take time for the blood bag plant to start production.
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India
India is the second-most populous country in the world, the seventh largest country by
land area, and the most populous democracy. Bounded by the Indian Ocean on the
south, the Arabian Sea on the southwest, and the Bay of Bengal on the southeast, it
shares land borders with Pakistan to the west, China, Nepal and Bhutan to the north
and Bangladesh and Myanmar to the east. In the Indian Ocean, India is in the vicinity
of Sri Lanka and the Maldives; its Andaman and Nicobar Islands share a maritime
border with Thailand and Indonesia. India is a federal union comprising 28 states and
eight Union Territories.

Burden of thalassaemia in India
India, with 1.38 billion people, is a multi-ethnic and culturally and linguistically diverse
population including around 8% of tribal groups according to the 15th Census of India
2011. The average prevalence of β-thalassaemia carriers is 3–4%, which translates
to 35–45 million carriers. Estimates indicate that there would be around 100 000
patients with a β-thalassaemia syndrome, but the exact numbers are not known
because of the absence of national registries (24). Extensive studies have provided
data on haemoglobinopathies; these include multicentre studies covering different
states conducted by the Indian Council of Medical Research, those undertaken by the
Anthropological Survey of India or as a part of state thalassaemia control programmes
as well as many Tribal surveys (25–27). At present, it is estimated that in India there
are 150 000 people living with a severe form of thalassaemia. The expected annual
number of affected births, estimated as 0.5/1000 live births for an average annual birth
cohort of 25 million, predicted 12 500 thalassaemia major births per year. Over a
period of 10 years, 125 000 more children will be added to the existing number of
thalassaemia major cases (28).

Given the heterogeneous and diverse population in India, it is not surprising that there
is a wide range of prevalence of thalassaemia in different states. In the eastern part of
India, the influence of HbE mutations also plays a part in defining the clinical
phenotype of the thalassaemia. In a multicentre study involving 56 780 individuals
from six major cities (Bengaluru, Kolkata, Dibrugarh, Ludhiana, Mumbai and
Vadodara) between 2000 and 2005, it was estimated that the prevalence of Hb
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disorders ranged between 3.1% and 31.8% (29). The type of thalassaemia also varied
with β-thalassaemia being the predominant disease seen in Bengaluru (overall 3.1%;
β-thalassaemia 2.16%), Ludhiana (overall 5.2%; β-thalassaemia 3.96%), Mumbai
(overall 3.48%; β-thalassaemia 2.55%) and Vadodara (overall 3.38%; β-thalassaemia
2.68%), while in Kolkata, both β-thalassaemia trait and HbE disease were equally
prevalent (overall 8.3%; β-thalassaemia 3.64; HbE 3.92%) and in Dibrugarh, it was
predominantly HbE disease (overall 31.8%; HbE disease 29.2%). In another study
involving 1291 subjects in western Maharashtra, the incidence of Hb disorders was
11.43% with the main disease being β-thalassaemia major (30). An analysis of 1015
subjects with anaemia in Odisha between 1994 and 2003 revealed a prevalence of Hb
disorders in 65.7% of the subjects with it predominantly being the sickle cell trait
(29.8%) followed by the β-thalassaemia trait in 18.2% (31). A higher frequency has
been observed in certain communities, such as Sindhis, Punjabis, Gujaratis, Bengalis,
Mahars, Kolis, Saraswats, Lohanas and Gaurs (32). Within each state, the prevalence
varies based on the presence of ethnic groups (33). Limited micromapping has shown
an uneven distribution in frequencies of β-thalassaemia carriers in different districts of
Maharashtra (1–6%) and Gujarat (0–9.5%) within small geographical regions (34).
HbE is prevalent in the northeastern and eastern regions where the frequencies of
HbE carriers range from 3% to over 50%, while HbS is predominantly seen among the
Scheduled Tribes, Scheduled Castes and other backward castes with carrier
frequencies varying from 5% to 35% in many groups (35). Co-inheritance of these Hb
variants with β-thalassaemia is not uncommon particularly in regions where both are
prevalent.
Guidelines for uniform management as well as prevention, screening of school and
college students, antenatal screening and prenatal testing for thalassaemia were
compiled and circulated by the blood cell of the National Health Mission (NHM) through
the Ministry of Health and Family Welfare (MoHFW) in 2016 (36). Many facets of these
guidelines have been implemented and training programmes are ongoing. The NHM
document has also described the reported prevalence of haemoglobinopathies from
several states of India.
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Fig. 4. Reported prevalence of haemoglobinopathies from India (36)

Blood transfusion services in India
It has been estimated that 2 million units of packed red cells are needed for transfusion
of thalassaemia patients in India (37). An assessment of blood banks across the
country was performed by the MoHFW in 2016 (38). This assessment identified 2626
functional blood banks excluding military blood banks. The public and not-for-profit
sectors together owned 76% of the blood banks in India and the private sector owned
24%. Around 61% of the blood banks were in located in eight states – Maharashtra
(11.7%), Tamil Nadu (10.1%), Uttar Pradesh (9.4%), Karnataka (7%), Kerala (6.3%),
Telangana (5.8%), Gujarat (5.1%) and Madhya Pradesh (5%). Except Maharashtra
and Gujarat, these states do not have a very high prevalence of thalassaemia. If the
number of blood banks per million population is considered, states such as Bihar (0.7
blood banks), Jharkhand (1.2), Uttar Pradesh (1.2), West Bengal (1.3), Rajasthan
(1.5), Madhya Pradesh (1.8), Manipur (1.8), Odisha (1.9), Assam (2), Nagaland (2),
Meghalaya (2) and Chhattisgarh (2) recorded less than the national average of 2.2. A
majority of these states have a high prevalence of thalassaemia either in the entire
state or within specific ethnic communities that are resident within the state. Between
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January and December 2015, the annual blood collection reported from all the blood
banks was 11 645 791, of which 71.9% (8 378 692) units were through voluntary blood
donations and the remaining were from replacement donations. The average annual
collection of blood units of each of the blood banks in the country was 4789 units. The
annual collection of blood units per 100 individuals was found to be around 1% in India,
which meets the WHO recommendation that 1% of the population can meet a nation’s
most basic requirements for blood. However, there are huge disparities in the
collection of blood between various states. Bihar collected only 0.2 units of blood per
100 population followed by Arunachal Pradesh (0.4), Meghalaya (0.5), Nagaland (0.5),
Jharkhand (0.5) and Uttar Pradesh (0.5). A recent estimate by the National AIDS
Control programme (NACO) for the MoHFW has suggested that the annual demand
is 14.6 million units whereas the collection in 2017 was 11.1 million units (39).

Though 91.5% of the blood banks reported adhering to the guidelines of the NBTC,
only 12.6% and 11.2% of the blood banks in India have enrolled themselves for
External Quality Assurance Schemes (EQAS) by recognized providers for
immunohaematology and TTIs, respectively. The mean assessment score of blood
banks in the country was 62 (SD 11.19). Most of the blood banks that scored less than
or equal to 35 were in Uttar Pradesh (13; 5% of all blood banks), followed by Bihar (6;
8% of all blood banks) and Odisha (3; 4% of all blood banks). The blood banks that
reported a higher proportion of voluntary blood donation indicated a higher mean
assessment score. Nineteen states have recorded more than the national average of
71.9%. States and Union Territories such as Dadra and Nagar Haveli, Arunachal
Pradesh, Maharashtra, Tripura, Tamil Nadu, Daman and Diu, Uttarakhand,
Chandigarh, West Bengal, Kerala, Andaman and Nicobar, and Himachal Pradesh
reported more than 80% voluntary blood donation. States and Union Territories such
as Meghalaya, Uttar Pradesh, Manipur, Chhattisgarh, Delhi, Assam, Bihar, Jharkhand,
Puducherry, and Jammu and Kashmir reported less than 60% of voluntary blood
donation. This difference may be related to the incorrect practice of considering near
relatives as voluntary donors. Repeat donations are also low (0–30%) due to lack of
customer satisfaction and donor loyalty.
The National Blood Cell under the NHM, Government of India was set up in May 2014.
It envisaged a comprehensive, efficient and total quality management approach for
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building a sustainable, national, integrated and standardized blood programme to
ensure the accessibility, adequacy, safety and quality of blood. The grant-in-aid
provided under the NRHM/NHM to state governments for strengthening/setting up
blood banks and blood storage centres is channelled through the National Blood Cell.
The National Blood Cell also facilitates specialized services for chronically transfused
patients and monitors and supports all aspects of blood services in the country. The
National Blood Cell coordinates and liaises with the different arms of the MoHFW for
efficient functioning. It has the following mandate:
•

To adopt a comprehensive approach to the blood services rather than just
focusing on disease transfusion through blood and blood products.

•

To plan a long-term sustainable programme for blood services.

•

To bring self-sufficiency in the blood services in all regions of the country.

•

To ensure access to safe blood to far-flung and remote areas of the country
so that the blood is available when and wherever required.

•

To deal with issues of inequitable distribution of blood leading to surplus in
some areas and severe scarcity in others.

•

To organize continuous and periodic monitoring of all activities of blood
services for providing support to the NHM.

•

To conduct regular financial audit of all aspects of blood services for efficient
use of resources.

•

To strengthen the supply chain of critical consumables to ensure proper
functioning.

•

To address the issue of maintenance of equipment in government blood
banks.

•

To facilitate specialized services for chronically transfused patients.

•

To establish coordination among the various divisions dealing with regulations
and management of blood services.

To fulfil this mandate, the NHM has made 1599 blood storage units functional which
are part of first referral units (FRUs) and subdistricts and some of the primary health
centres which have a high load for delivery. The aim is to ensure that all districts have
functional blood banks and all FRUs have at least blood storage centres. Eighty-nine
districts still do not have blood banks and the NHM has supported the setting up of 74
blood banks in various states. To facilitate voluntary blood donation, the NHM has
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been working towards strengthening blood services including mobile blood collection
and transportation vans with dedicated workforce to augment the availability of blood.
A detailed gap analysis carried out under the NHM in the states has revealed that most
of the blood banks were facing shortage of human resource and equipment. Under the
NHM, states have been supported with the required human resource and equipment
in the blood banks and regular assessment is being done after 2 years for upgrading
the blood services.

The NHM has also been working towards developing a network of blood banks and
blood storage centres and the e-Raktkosh, which is an integrated Blood Bank
Management Information System. This web-based mechanism interconnects all the
blood banks of a state into a single network (40). This has been developed with the
objectives of providing safe and adequate blood supplies, reducing the turnaround
time, developing a network of blood banks, ensuring that all blood banks adhere to the
Drugs and Cosmetics Act, having real-time availability of blood stock, a statewise/district-wise donor database and generating various reports for blood bank
officials and administrators. In the past 3 years, e-Raktkosh has made an impressive
progress and more than 1900 blood banks across the country are using this
application for their day-to-day activities with real-time updates of blood stock. The eRaktkosh portal is extensively used by patients/citizens for their requirements related
to blood, finding the location of blood banks, maintaining donation repository, details
about blood donation camps, etc. The application has become a one-stop solution for
both blood banks and patients who need blood and blood-related products. This
platform has been recognized and awarded for its excellence and contribution to
society in the “Gems of Digital India Award 2019”.

It is worth noting that many efforts may not trickle down to the grassroots. Dr J.S.
Arora, General Secretary, National Thalassaemia Welfare Society expressed concern
in a newspaper interview in 2019 on World Thalassaemia Day that despite the National
Blood Transfusion Council (NBTC) issuing directions to provide free blood to all
persons with thalassaemia in 2014 and NHM publishing guidelines on management
and prevention of haemoglobinopathies in 2016, the optimum Hb level is not
maintained in most patients with thalassaemia. It has been observed that 50–60% of
persons with thalassaemia have Hb levels of less than 9 g/dL (41).
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Indonesia
Indonesia is a country in South-East Asia and Oceania, between the Indian and Pacific
oceans. It consists of more than 17 000 islands, including Sumatra, Java, Borneo,
Sulawesi and New Guinea (Papua). Indonesia is the largest island country and has
over 300 ethnic groups; 95% of those are of Native Indonesian ancestry. Javanese is
the largest group with 100 million people (42%), followed by Sundanese, whose
number is nearly 40 million (15%). Administratively, Indonesia is divided into provinces
which are the 34 largest subdivisions of the country and the highest tier of the local
government. Provinces are further divided into regencies and cities, which are in turn
subdivided into districts.

Burden of thalassaemia in Indonesia
Early studies have estimated that there is a high prevalence of thalassaemia carrier
status in the Indonesian population with a prevalence of 3–20% for α-thalassaemia
carrier, 3% for β-thalassaemia carrier and 1–33% for HbE carrier (42). Because of the
diversity of the genetic background, there is a difference in the carrier frequency of βthalassaemia (5–10%), HbE (1–33%) and α-thalassaemia (6–16%) depending upon
the ethnic population. This variation can result in unequal anticipated carrier testing
and prenatal testing workload and therefore, the carrier screening protocol and
prenatal testing must be designed on a regional basis (43).

Fig. 5. Distribution of thalassaemia trait in five provinces of Indonesia (44)
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In a study, 241 volunteers were screened in the Yogyakarta special region between
2012 and 2015 (44). Among the 241 volunteers, 44 (18.2%) were diagnosed as βthalassaemia carriers, 30 (12.4%) as α-thalassaemia carriers as well as HbE carriers,
and 1 as α-β-thalassaemia carrier. There was no difference in the number of carriers
detected during the 3 years of the study suggesting no increase in the prevalence
(Fig. 5).

Because of the ethnic variation in frequency of thalassaemia in the Indonesian
population, various studies have tried to identify specific genetic mutations in each
population as this will help in genetic diagnosis and screening. Another study on 209
β-thalassaemia Javanese patients from Central Java, using a combination of multiple
detection methods, identified 14 alleles that accounted for more than 85% of patients
(45). Identification of the most prevalent alleles would help in improving the βthalassaemia screening for the Javanese, which is one of the major ethnic groups in
Indonesia. Specific variants have also been identified in the α-thalassaemia gene,
which includes the identification of HbO mutation in Indonesia. Heterozygous
mutations for HbOIna were identified from the Bugis, Toraja, Makassar and Kajang
ethnic populations, but not from the other populations (46).

The data from the Indonesian Thalassaemia Foundation/Association of Parents of
Thalassaemia Patients Indonesia (YTI/POPTI) reveal that the number of patients with
thalassaemia in Indonesia has increased from 4896 in 2012 to 9028 in 2018.
According to the latest estimates, there are 10 531 thalassaemia patients, and more
than 2500 newborns have thalassaemia each year in Indonesia (47). Since there is an
absence of a national registry and the data available are fragmented, there may be
many undiagnosed patients. Separate databases are available in major thalassaemia
centres such as the Cipto Mangunkusumo Hospital, which is a national referral
hospital.

The treatment of thalassaemia has been included in the benefits package of the
government health insurance programme for the poor (JAMKSESMAS) since 2010
and the national health insurance (NHI) programme since 2014. Supportive measures
such as blood transfusion and iron chelation are the mainstay of management of
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patients with thalassaemia (48). National guidelines are available on the indications
and frequency of transfusion based on international guidelines.

Blood transfusion services in Indonesia
The Indonesian Red Cross Society or Palang Merah Indonesia (PMI) is the national
blood service agency which ensures that there is an adequate and safe supply of blood
for all patients who require transfusions. The blood supply for all hospitals is performed
by blood centres that either belong to the PMI or government hospitals. About 80% of
blood donations occur through VNRBD, while the rest are replacement donations and
occasionally through paid donations. The PMI targets 4.5 million blood bags annually
in accordance with the national blood needs. Every week, Indonesia needs 60–70 000
blood donations to ensure enough supplies for people in need. However, with the
current donation rate, Indonesia can only fulfil around half of the blood demand. The
others must depend on blood provided by families, friends or even on paid donations.
Moreover, there is an unequal distribution of blood supply in Indonesia. According to
the MoH, in 2014 Jakarta had an excess supply of blood of 60%, while there was a
96.3% shortage of blood in West Papua. The variable quality of blood services
throughout the country also reflects in the fact that 0.46% of national donations
originate from paid donors and these paid donors were found in 34 remote areas (49).
The transfusion rates in patients with thalassaemia are not encouraging and a study
from the Cipto Mangunkusumo Hospital showed that only 30% of patients complied
with the recommendation to come for a transfusion before their Hb levels fell below 9
g/dL (48). Studies on the quality of life (QoL) have also shown a reduced QoL
compared to controls in children with thalassaemia (50).
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Maldives
The Maldives is an island nation that comprises 20 natural atolls with only 200
inhabited islands, which are in the southwest of India. As of July 2020, the population
of Maldives is 540 544. The population distribution varies considerably among the 200
islands. The population of atolls ranges from 5000 to 20 000, and some islands have
less than 500 people. Maldives was urbanized by immigrants from South Asia, mainly
from South India and Sri Lanka (51). The largest ethnic group is Dhivehin, i.e. the
Maldivians, native to the historic region of the Maldives Islands comprising today's
Republic of Maldives and the island of Minicoy in the Union Territory of Lakshadweep,
India. They share the same culture and speak the Dhivehi language. They are
principally an Indo-Aryan people, having traces of Middle Eastern, South Asian,
Austronesian and African genes in the population.

Burden of thalassaemia in Maldives
Initial studies from the early 1970s have suggested a thalassaemia carrier frequency
of 10.1% (52). In 1985, a collaboration between the Government of Maldives and the
Society for Health Education (SHE) established the National Thalassaemia Screening
Programme. An analysis of this programme was published in 2020 (53). Blood
samples were collected from 110 504 participants between 1992 and 2015, which
is nearly 30% of the entire population. Hb and red blood cell indices were measured
on automated haematology analysers. The quantitation of Hb, HbA2, HbF, and other
abnormal Hb variants were assessed by HPLC. Molecular analysis was performed for
the most common mutations in South-East Asia for only 874 individuals either
heterozygous or homozygous for these mutations using reverse dot blot hybridization.
The β-thalassaemia carrier frequency was estimated to be 16.2%. Molecular diagnosis
of 874 β-thalassaemia carriers/major was performed for the most common seven
mutations in South-East Asia; of these, 139 patients were diagnosed as βthalassaemia major. This analysis showed that the most common mutations among
the 874 individuals were IVS1+5G>C (678; 77.6%), followed by CD30 (136; 15.6%).
The IVS1+5G>C (76%) mutation is consistent with what has been found in Sri Lanka
and India. The second most common mutation was CD30 (13.3%), which is common
among patients with β-thalassaemia in Italy. This indicates that Maldives might have
its own distinct molecular genetic epidemiology profile. Besides β-thalassaemia, there
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are α-thalassaemia carriers 2.1%, HbE carriers 0.9%, HbS carriers 0.13% and HbD
carriers 0.43% (54).
The frequency of β-thalassaemia varies significantly among the 20 different atolls in
Maldives. The carrier frequency ranged from 6.8% in the Meemu Atoll to 23.8% in the
Noonu Atoll and Haa Dhalu Atoll (Fig. 6) (53). As per the 2018 Maldivian Blood
Services Report, 874 patients have been registered in Maldives. About 10–15 new
patients with thalassaemia are registered every year. A study performed in 2016 to
understand the reasons for couples not testing for thalassaemia before or after
marriage showed that participants did not undergo carrier tests because of poor
awareness and a lack of understanding of the devastating consequences of the
condition (55). The outcomes of not testing were distressing for most participants. In
view of the high carrier frequency, the present regulations in Maldives make it
compulsory for couples to test for thalassaemia before getting married. Authorities do
not forbid marriage between two carriers, but it is discouraged.
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Fig. 6. Prevalence of β-thalassaemia and mutation distribution among the 20 atolls in
Maldives (53)
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Blood transfusion services in Maldives
Maldivian Blood Services (MBS) was formed on 1 November 2012 by merging the
National Thalassaemia Centre (NTC) and the National Blood Transfusion Services
(NBTS). The aim was to provide better service to patients suffering from
haematological disorders such as thalassaemia and other haemoglobinopathies and
to provide safe blood to those who are in need. MBS, located in Male, has two main
units: Thalassaemia and Other Haemoglobinopathies Centre (TOHC) and Central
Blood Bank (CBB). The TOHC was till recently the only centre throughout Maldives
serving exclusively to patients of thalassaemia and other haemoglobinopathies. In
December 2018, the government in partnership with WHO inaugurated a nationwide
system to facilitate convenient treatment to patients suffering from thalassaemia by
improving access to safe blood, transfusion services and treatment for patients with
thalassaemia. The Thalassaemia Society of Addu was inaugurated in October 2019
and is being operated in collaboration with the NTC and the Thalassaemia Society of
Maldives. All patients with haemoglobinopathies can get registered at MBS to avail
free services.

Blood donation occurs either through direct donations at the NBC and the Indira
Gandhi Memorial Hospital (IGMH) or through outdoor blood donation camps. Mobile
units are used for blood donation drives and three camps are organized each month.
Each camp usually collects 35–40 units of blood although occasionally up to 120 units
may be collected. Monthly blood collection is about 300 units by the IGMH and about
500 units by the NTC (17). About 70–80% of blood units are collected mainly from
family replacement donors and directed donors for their own patients while there are
only 10–30% voluntary donations and no paid donors. Family members are avoided
as donors. A few blood banks on the other islands cater to their local population. A
WHO Mission report in 2014 suggested that despite the allocation of the MBS as the
NBC, there was less cooperation with the various blood banks in other hospitals, such
as the IGMH, which could alleviate shortages, especially when a rare blood type or an
antibody-free donor blood is sought (54). This lack of networking adds to delays in
finding a suitable donor for a patient and allows drop in pre-transfusion Hb.
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Myanmar
Myanmar is the largest of the Mainland South-East Asian states by area with a size of
676 578 sq. km (261 228 sq. miles). Myanmar is divided into seven states and seven
administrative regions. Myanmar is composed of 135 ethnic groups in which Kachin,
Kayah, Kayin, Chin, Mon, Bamar, Rakhine and Shan are the major indigenous races.

Burden of thalassaemia in Myanmar
Myanmar has a high prevalence of haemoglobinopathies: α-thalassaemia 10–56.9%,
HbE 1–28.3%, β-thalassaemia 0.54–4.07%. It was estimated that 1–4.9 births per
1000 infants are with a major haemoglobinopathy (56). In the 1960s and 1970s, the
Anaemia Research project reported the prevalence of thalassaemia trait among the
Burmese (Bamar) to be 4.3% and that of the β-thalassaemia trait 0.54% (57).
Prevalence rates of α-thalassaemia also ranged from 10% to 56.9%. A study in 2011
reported a β-thalassaemia carrier rate of 4.07% among asymptomatic Myanmar
subjects aged 16–45 years (58). The prevalence of HbE trait was reported to be
between 1% and 28% among the various races of Myanmar. There is no national
thalassaemia registry, but hospital registries exist. According to hospital-based
records, HbE-β-thalassaemia accounts for 46–58%, β-thalassaemia for 5.4–22% and
α-thalassaemia for 6–37%. Studies have also focused on the types of mutations
prevalent in Myanmar. Molecular mutations associated with α-thalassaemia were first
described in 2001 and -α3,7 type of α-thalassaemia mutation is the most common
deletional type of mutations. The commonest genetic abnormalities in patients with
HbH disease is (--SEA/- α3,7) (53%) and (--SEA/- α4.2) (30%) (59,60). In 2002, 18 different
β-thalassaemia mutations were studied among patients with either thalassaemia
major or thalassaemia intermedia. The common mutations seen include CD 41/42 (TCCT), IVS1-1 (G-T), IVS1-5 (G-C) and CD17 (A-T) (61). A recent study compared
the spectrum of β-thalassaemia mutations seen in Myanmar with five of its
neighbouring countries – China, Laos, Thailand, India and Bangladesh (62). The
common β-thalassaemia mutations were seen in all neighbouring countries though at
different frequencies while several mutations described in other countries were rare in
Myanmar. A molecular survey during annual check-up of 300 anonymous Myanmar
workers in a factory in North-East Thailand revealed the presence of thalassaemia
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mutations in 61.5%, mainly α-thalassaemia (39%) and HbE (19.3%) with a very low
prevalence of β-thalassaemia (2%) (63).

The prevalence of HbE disease has been estimated to be 25% in the general
population in Myanmar but some studies have reported higher figures. In a study on
132 schoolchildren at the Yangon Children hospital, the prevalence of HbE disease
was 63.6% (64).
Myanmar has four established haematology centres plus one new centre from the
army. The thalassaemia registry is thus hospital-based only. In 2019, 496 new
paediatric thalassaemia patients were registered in two paediatric centres, while about
400 new adult thalassaemia patients were registered in three adult centres. Yangong
Children’s Hospital has 4000 registered thalassaemia patients – 1433 received
transfusions in 2016, 1496 in 2017 and 1510 in 2018. Overall, five haematology
centres provide services for transfusion of definite thalassaemia care, but patients get
transfused at local hospitals as well.

Blood transfusion services in Myanmar
The first blood bank facility was established at the Yangon General Hospital in 1945
and is presently known as the NBC. In 1962, a national blood bank committee was
created and the following year a voluntary blood donation programme was formalized.
Set up in 1920, the Myanmar Red Cross Society (MRCS) initiated blood donation
activities in 1961 to help improve blood donation. The MRCS supports the “national
blood and blood product law” (enacted in January 2003) to save patient’s lives through
blood transfusion of quality assured blood and blood products and to prevent TTIs
through the promotion of VNRBD (65). Myanmar has a nationally coordinated BTS
that is managed by the government and the NBC is the technical hub for developing
BTS in the country. A blood and blood products law was enacted in 2003 to implement
a regulatory mechanism in Myanmar. The Department of Health manages the NBC,
which has two national blood banks at the Yangon General Hospital and Mandalay
General Hospital, with an annual demand of 180 000 units of blood. Nationally, there
are 359 hospital-based blood banks with an annual demand of 200 000 units of blood.
Nearly 100 hospitals of varying levels and 324 townships and station level hospitals
perform regular blood transfusions. Blood bank guidelines which represented the
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country’s needs were launched in 2011. Training on these guidelines was started and
covered the entire country by 2014. Since then, the blood transfusion service around
the country developed a uniform registration system (66).

Fig. 7. Blood transfusion services connected to the National Blood Centre in Myanmar
(66)
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A survey done ahead of the World Blood Donor Day on 14 June showed that many
people in Myanmar believed that the blood donation process was either too
complicated or risky to get involved. In 2000, the percentage of voluntary donors was
34.9%. Several voluntary organizations assist in donor recruitment and blood
donation. In 2018, Myanmar's NBC in Yangon provided 438 000 units of blood with
72% being donated by volunteers and 32% was used in Yangon. Presently, the
voluntary blood donation in the country has improved to 85%. The NBC is supplying
enough safe blood for 14 hospitals in the Yangon region and acting as a source of
safe blood for other hospitals in the country. Despite this, shortage of blood is still a
problem. During the World Blood Donor Day on 14 June 2019, it was reported by the
National Blood Bank that it was around 100 litres short of the blood that was required
by patients every day – the equivalent of 600 blood transfusions.
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Nepal
Nepal is a landlocked country situated mainly in the Himalayas in South Asia and is
bordered by China, India and Bangladesh. The Nepalis are descendants of three
major migrations from India, Tibet and North Burma, and the Chinese province of
Yunnan via Assam. Among the earliest inhabitants were the Kirat of the eastern
region, Newars of the Kathmandu Valley, aboriginal Tharus of the Terai plains and the
Khas Pahari people of the far-western hills. Nepal is composed of seven provinces,
which are divided into 77 districts. Nepal has a diverse ethnic group of population.
Though most of the geographical places of the country share mixed ethnicity, some
ethnic group seems predominant in certain geographical locations of the country.

Burden of thalassaemia in Nepal
There has been no study to estimate the burden of thalassaemia in Nepal and a
majority are hospital-based data (67). Sickle cell disease is commonly detected in
Banke, Bardiya, Dang, Kailali and Kanchanpur, while thalassaemia cases can be
found in any part of country. In Nepal, β-thalassaemia is more common and was found
mostly in low land Terai region and some in the mid-hill region and, unlike sickle cell
disease, it is believed to be prevalent in all ethnic communities.
A hospital-based study that examined 138 electrophoresis samples identified βthalassaemia in 34 cases (β-thalassaemia trait in 26 and homozygous β-thalassaemia
in eight), sickle cell anaemia in 21, α-thalassaemia in 11 and HbE disease in five.
Incidentally, the Tharu community had the highest incidence of haemoglobinopathies
(68). Another study done in Kathmandu on 163 electrophoretic samples showed the
presence of a haemoglobinopathy in 47.3% with the common diagnosis being sickleβ thalassaemia in 14.1%, sickle cell disease (13.5%) and β-thalassaemia in 12.9%
(69). Both studies carried the obvious bias of prevalence being estimated based on
laboratory tests that were ordered for patients suffering from anaemia.

A recent study retrospectively analysed 4018 samples collected at five different Nepal
government testing sites during 2016–2018. Of the 4018 cases, 1470 or 36.5%
showed the presence of a haemoglobinopathy-related disorder (70). Sickle cell
disease (homozygous or trait) was identified in 17.4% while β-thalassaemia
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(homozygous and trait) was identified in 10% and HbE disease in 2.1%. It was
observed that the types of haemoglobinopathy were not uniformly distributed in
different geographical areas (Fig. 8). Sickle cell was more prevalent in Provinces 5, 6
and 7 while β-thalassaemia was more prevalent in Provinces 2, 3 and 4. In Province
1, HbE was the most common.

Fig. 8. Distribution of haemoglobinopathy among the various provinces of Nepal (70)

This study also recognized that all the ethnic groups did not have the same distribution
of haemoglobinopathies (Table 1). The Tharus predominantly had sickle cell disease
while the Newars, Chhetris, Brahmins and the Dalits predominantly had βthalassaemia. The Rajbanshis predominantly had HbE disease while the Muslims had
similar prevalence of HbE disease and β-thalassaemia. The Janjatis again had a
combination of β-thalassaemia along with minor haemoglobinopathies.

Interestingly, studies in the early 2000s suggested that there was a correlation
between the presence of malaria and the presence of α-thalassaemia (71). In a study
involving four ethnic groups in a lowland area of Nepal, it was shown that the group
that had lived for many decades in a malaria-endemic lowland area, the Danuwar, had
a high prevalence of α+-thalassaemia (79.4%) and low prevalence of HbE and G6PD
deficiency. On the other hand, much lower prevalence of α+-thalassaemia was
observed in the Newar (20.5%), Parbate (16.5%) and Tamang (8.8%) regions, which
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until the 1950s, all spent their hot-season nights in malaria-free areas at higher
altitudes (72).

Blood transfusion services in Nepal
The National Policy for Blood Safety was approved in 1991 and the Government of
Nepal mandated the Nepal Red Cross Society as the sole authority for conducting
blood programmes in Nepal. The National Blood Policy has since been revised in 2006
and 2012, providing the regulations for ensuring the people of Nepal to have access
to a safe and adequate supply of blood and blood products (21). There is a National
Technical Advisory Committee (NTAC) which provides advice on blood-related
technical matters, and falls under the National Steering Committee, part of the Ministry
of Health and Population (MoHP). Under the MoHP, the National Public Health
Laboratory (NPHL) functions as the reference centre and encourages all aspects of
blood safety (policy, guidelines, protocols and SOPs). The draft guidelines for the
management of thalassaemia and sickle cell anaemia was issued by the MoHP in
2017.

Voluntary blood collection was introduced in 1982 and the Central Blood Transfusion
Service (BTS) in Kathmandu reached 90% VNRBD in 2009. According to the Nepal
Red Cross Society (May 2020), there are 113 Blood Transfusion Service Centres
(BTSCs) but only 13 blood banks have the blood component service. The BTSCs in
Nepal are divided into the following: (i) Central BTSC (1) in Kathmandu; (ii) Regional
BTSCs (4) in Biratnagar, Pokhara, Nepalgunj, Chitwan; (iii) district BTSCs; (iv)
emergency BTSCs; and (v) hospital units.
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Fig. 9. Geographical distribution of Blood Transfusion Service Centres in Nepal 2011
(73)

More than 85–90% of blood is collected through VNRBD, but sometimes replacement
is also being requested by blood banks at times of blood shortage mainly during or
immediately after festivals such as Dussehra, Deepawali, Chhat and during the cold
seasons. In 2009–2010, it was estimated that a total of 156 278 units of blood were
collected, which was approximately 0.62% of the total population of the country.
Though blood transfusion centres are present in 50 of the 77 districts in Nepal, many
still lack in quality transfusion facilities and therefore several patients travel to
Kathmandu for regular blood transfusions.
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Sri Lanka
Sri Lanka is an island in the Indian Ocean about 28 km (18 miles) off the southeastern
coast of India. The Sinhalese make up 74.9% of the population and are concentrated
in the densely populated southwest and central parts of the island. The Sri Lankan
Tamils, who live predominantly in the north and east of the island, form the largest
minority group at 11.1% of the population. The Moors, descendants of Arab traders,
form the third largest ethnic group at 9.3% of the population and are mostly
concentrated in urban areas in the southern parts of the island with substantial
populations in the central and eastern provinces. Indian Tamils form the other distinct
ethnic group comprising 4.1% of the population. Other smaller minorities include the
Malays, the Burghers and ethnic Chinese migrants. Administratively, there are nine
provinces in Sri Lanka.

Burden of thalassaemia in Sri Lanka
de Silva et al. in a study published in 2000 studied blood samples from 703 patients
with β-thalassaemia and 1600 schoolchildren (74). Although 23 different βthalassaemia mutations were found, three accounted for the thalassaemia phenotype
in about 70% of patients, most of whom are homozygotes or compound heterozygotes
for IVS1-5 (G-->C) or IVS1-1 (G-->A). The third common mutation, codon 26 (G-->A),
which produces HbE, interacts with one or other of these mutations to produce HbEβ-thalassaemia; this comprises 13.0–30.9% of cases in the main centres. As a subset
from the above study, samples from 472 patients were analysed to determine the αglobin genotype and overall 15.5% patients were carriers for deletion forms of α+thalassaemia. A study of the average gene frequencies estimated that there will be
more than 2000 patients requiring treatment at any point of time in the future, of which
those with HbE-β-thalassaemia will account for about 40%. Of the 1547 patients,
genetic data were available for 1379 (75). A recent hospital-based survey described
data on 1774 patients from 23 centres (76). Among these, 1219 patients (68.7%) had
homozygous β-thalassaemia, 360 patients (20.3%) had HbE-β-thalassaemia, and 50
patients (2%) had sickle β-thalassaemia. This study also examined the annual births
with thalassaemia between 1996 and 2014; the annual number of births of patients
with β-thalassaemia varied from 45 to 55 with little evidence of reduction over 19 years.
Ethnically, 1450 patients were Sinhalese (at 82.6%, higher than the national
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representation at 72%), 211 were Moors (at 12.0%, higher than the national
representation at 7.1%). Ninety-three were Tamils (at 5.3% less than one third of the
national representation at 18%) and two patients were Burgher (0.11%). Overall, it is
estimated that the carrier rate is 2–4%, estimated prevalence of 2000–3000 cases and
annual incidence of 80–100 cases out of 350 000 births (77). In Sri Lanka, coinheritance of either excess α-globin genes in β-thalassaemia heterozygotes or αglobin gene deletions in β-thalassaemia homozygotes is a significant factor in
modulating disease severity (78).
The burden of thalassaemia in Sri Lanka is not uniform with a high burden of disease
in the North West province, North Central Province and Central Province. To
adequately manage these patients with thalassaemia, four regional thalassaemia
centres are located in the provinces with the highest burden of disease. Since 1995,
all thalassaemia patients were exempted from the requirement of finding donor
replacements for blood transfusions, which considerably improved the quality of care
for thalassaemia patients in Sri Lanka. As per the National Health Policy, all
medications including blood and chelating agents are available free of charge for all
patients in the country. Despite these efforts, patients with thalassaemia continue to
have a lower QoL. In a study involving 271 children with TDT from the three largest
thalassaemia centres of Sri Lanka, it was found that the mean health-related QoL
scores was significantly lower in patients compared to controls. In addition, QoL scores
in psychological health, emotional functioning and social functioning were significantly
lower in patients with HbE-β-thalassaemia compared to those with β-thalassaemia
major (79).
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Fig. 10. Distribution of thalassaemia centres with patient numbers in Sri Lanka (76)

Blood transfusion services in Sri Lanka
Sri Lanka has one of the best blood transfusion services (BTS) in South Asia, which
is nationally coordinated and managed by the government. The National Blood
Transfusion Service (NBTS) Sri Lanka is a special campaign under the MoH. It has a
unique role providing timely supply of quality assured blood and blood components
and related laboratory, clinical, academic and research services for the entire
government sector hospitals and for most of the private sector hospitals in the country.
The NBTS was established in 1999 and is designated as a WHO Collaborating Centre
for Blood Transfusion Service in 2018. The NBTS is the sole supplier of blood and
blood products to all state hospitals and some of the private hospitals, which are
registered under the MoH for supply of blood and blood products. There are 1042
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government hospitals and 115 hospitals in the private sector. Having its headquarters
at the NBC, the NBTS has 103 blood banks (both hospital-based in the public and
private sectors) across the country, which are grouped into 19 clusters. There are no
standalone blood banks in the nongovernment organization (NGO) or private sector.
These blood banks are categorized as the NBC (headquarters), Cluster Centres and
Peripheral Blood Banks.

The annual collections have been steadily growing with 450 640 units being collected
in 2018; of these, 417 153 being mobile collections (80). The total discarded units for
2018 were 30 341 with the majority (23 617) being discarded post expiry. About 60–
70% of donations are separated into blood components; 100% of Sri Lankan blood
donors are VNRBDs and there is no paid donation. The NBC has established a system
of functional hospital transfusion committee in all hospitals. It has also established a
haemovigilance system and irradiation facility. In recognition of its services, the NBTS
was awarded the International Society of Blood Transfusion (ISBT) Award for
Developing Countries in 2012 from among 28 competitors and the NBTS Sri Lanka
was selected as the best transfusion service among developing countries.
Though clear guidelines are laid down for transfusion in patients with β-thalassaemia
major, guidelines are lacking for patients with HbE-β-thalassaemia. In a study on 328
patients (83% β-thalassaemia major, 16% HbE-β-thalassaemia), involving three large
thalassaemia centres in Sri Lanka, it was observed that over 60% of regularly
transfused patients with β-thalassaemia have low pre-transfusion Hb levels and did
not maintain pre-transfusion Hb levels of >9 g/dL despite receiving large transfusion
volumes (81). In addition, it was noted that patients with HbE-β-thalassaemia were
also under-transfused. A companion study also noted that this disease had a
significant impact on psychological health of the children and mothers with a large
proportion reporting abnormal psychological symptom scores (82).
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Thailand
Thailand has a diverse ethnic make-up and the Thai government officially recognizes
62 ethnic communities. The majority (34.1%) are Central Thai (with Khorat Thai) (83).
Mountain people and ethnic communities in the northeast comprise about 24.9%.
Other major ethnic communities include Khon Muang (9.9%, also called Northern
Thais); Pak Tai (7.5%, also called Southern Thais) and Khmer Leu (2.3%, also called
Northern Khmer). There is a significant number of Thai Chinese in Thailand and up to
14% of Thais may have Chinese origins. Another major group comprising one third of
Thailand's population are the Isan people who are ethnic Lao with some belonging to
the Khmer minority.

Burden of thalassaemia in Thailand
Thailand was the first country to report thalassaemia in the non-Mediterranean
population in 1954 when they described a series of 32 cases (84). The prevalence of
haemoglobinopathy varies in the Asia Pacific region and in Thailand the prevalence of
α-thalassaemia varies between 5.5% and 30%, β-thalassaemia between 1% and 9%
and HbE disease between 5% and 50% (85). The other type that is commonly seen is
Hb CS. A hospital registry study involving 4303 patients between 1974 and 2013
showed that the majority were HbE-β-thalassaemia (61%) followed by HbH or αthalassaemia (16%), Hb CS (15.7%) and β-thalassaemia (7.3%) (86). With the high
prevalence and diverse heterogeneity of thalassaemia and haemoglobinopathies,
around 60 thalassaemia syndromes are encountered in Thailand. A national
prevention and control programme for thalassaemia was established throughout
Thailand in 1992 with the support of the National Health Security Office (NHSO). Since
the clinical manifestations of these genetic mutations can vary from their presentation
as a transfusion-dependent disease to a mild asymptomatic illness, it is worth finding
whether there are specific geographical distributions for each of the thalassaemic
syndromes.

Chaibunruang et al. assessed the impact of the national control programme by
studying 350 cord blood samples of newborns at the Maternal and Child Hospital,
Khon Kaen province, northeast Thailand between January and May 2012 (87). Among
the 350 newborns examined, thalassaemia genes were identified in 184 (52.6%)
cases with as many as 22 different genotypes. The most prevalent one was HbE
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(39.1%) along with α0-thalassaemia (3.1%), α+-thalassaemia (25.9%), Hb CS (5.4%)
and a very low incidence of heterozygous β-thalassaemia (0.6%).

Yamsri et al. in a study involving 21 068 unrelated subjects at a centre in northeast
Thailand showed that 2637 patients (12.5%) had a β-thalassaemia mutation while only
177 (0.84%) had HbE-β-thalassaemia and all had a thalassaemia intermedia
phenotype (88). In a study on 542 persons belonging to the four ethnic groups that
inhabit the lower region of northeast Thailand, i.e. the Laos, Khmer, Suay and Yer, the
prevalence of HbE disease was more than 50% along with a high incidence of α+thalassaemia (48.2%) in the Khmer group and a high prevalence of Hb CS and Hb
Pakse in the Yer and Suay ethnic groups (89). It is estimated that 3600 babies were
born with severe α-thalassaemia in Thailand in 2020 though there is geographical
variation. Heterogeneity is greatest in the north of the country. For α 0-thalassaemia,
the northernmost provinces of Chiang Rai, Phayao and Nan have predicted allele
frequencies of up to 2% while the allele frequencies for the neighbouring provinces of
Chiang Mai, Lampang and Phrae and the northeast are up to 4% (90). The predicted
allele frequencies are below 1% in the southern zone. Nuinoon et al. in a study of 116
voluntary blood donors from southern Thailand showed an overall frequency of
haemoglobinopathies of 12.9%, which were classified as follows: α-thalassaemia
(3.4%), heterozygous β-thalassaemia (0.9%) and HbE disease (8.7%) (91).

Blood transfusion services in Thailand
The National Blood Programme in Thailand started in 1966 as a mission designated
by the government to the Thai Red Cross Society (TRCS). The NBC TRCS was
initiated with technical assistance from the French government and began to function
in 1969. The TRCS has the responsibility for blood collection and delivery services
throughout the 76 provinces of Thailand. Key to these services are the NBC in
Bangkok and 12 Regional Blood Centres (RBCs) located in different provinces of the
country, all of which offer facilities for donation of blood, screening and distribution.
Both the NBC and RBCs distribute blood to hospitals in all provinces, as determined
by the government. At present, there are 12 RBCs along with branches in 157
provincial hospitals. For a population of 65 900 000, there are around 1 800 000 whole
blood collections annually. Overall, 2% of the adult eligible population donated blood.
All donated blood was through voluntary blood donors and there were no private blood
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collection centres (92). Nearly 94% of the blood collected is delivered to hospitals and
patients while the rest are discarded either due to infections or expiry. In a survey of
donor vigilance at the NBC TRCS between August and November 2011, of the 2789
responders, 81% indicated their willingness to donate every 3 months.
It is a challenge to make available and supply quality blood products in the periphery.
The reverse occurs in the capital, necessitating the transportation of more than 40%
of blood collected by the NBC in Bangkok out to areas of shortage throughout the
country. Blood is sent by public transportation: aeroplane, bus and van depending on
the available modes of transport and geographical locations of the provinces where
the RBCs are located. Modelling studies have looked at establishing low-cost blood
collection and distribution centres in areas where blood distribution centres are either
lacking or are too far (93).
Fig. 11. Distribution of National Blood Centres in Thailand (92)
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Timor-Leste
East Timor or Timor-Leste is an island country in South-East Asia. It comprises the
eastern half of the island of Timor, the nearby islands of Atauro and Jaco, and
Oecusse, an exclave on the northwestern side of the island surrounded by Indonesian
West Timor. Australia is the country's southern neighbour, separated by the Timor
Sea.

There are several distinct ethnic groups, most of whom are of mixed Austronesian and
Melanesian/Papuan descent. The largest Malayo-Polynesian ethnic groups are the
Tetum mainly in the north coast and around Dili and the Mambai in the central
mountains along with the Tukudede, the Galoli Kemak and the Baikeno. The main
tribes of predominantly Papuan origin include the Bunak, Fataluku and the Makasae.
In addition, there is a population of mixed East Timorese and Portuguese origin and a
small Chinese minority. Administratively, East Timor is divided into 13 municipalities,
which in turn are subdivided into 65 administrative posts, 442 villages and 2225
hamlets.

Burden of thalassaemia in Timor-Leste
There are sparse data available on the prevalence of thalassaemia in East Timor (94).
Chronic malnutrition, tuberculosis and anaemia among women seem to be the major
health challenges. A 2007 WHO epidemiological study on Hb disorders in countries of
the SEA Region estimated 25 births every year with β-thalassaemia major and HbEβ-thalassaemia (2).

Blood transfusion services in Timor-Leste
Blood donor recruitment and retention activities are coordinated nationally and funded
by the National Society, which is the Timor-Leste Red Cross. As of 2011, the national
blood bank in the capital Dili collected around 1500 units annually, while regional blood
banks located in Baucau, Maliana and Oecusse collected and processed a small
number of blood units (21). The national blood bank performs blood component
separation and encourages clinicians to use blood responsibly. In 2014, blood
transfusions were available only at six referral hospitals (Dili, Baucau, Suai, Maliana,
Oecusse and Maubisse), with seven districts lacking access to blood products,
resulting in a high number of deaths each year. To fast-track the development of blood
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transfusion services, the MoH established the country’s first ever National Blood Policy
in 2014 and National Blood Programme Strategic Plan 2015–2019 (95). The blood
supply is well below the demand; about 2400 units of blood were required (mostly for
managing pregnancy-related complications) in 2012, but only 1938 units were
collected. In 2014, 63% of blood supplies were from VNRBD with the rest from
patients’ relatives. Blood donation drives are organized only in the Dili district and
blood is collected only when needed. Following establishment of the national policy
and the strategic plan, the Timor-Leste Red Cross Society (CVTL) commenced its
blood programme in 2016, engaging volunteer blood donors. It received technical
assistance through the participation of a VNRBD workshop in Seoul, Korea (April
2016) and the Australian Red Cross. It receives financial support from the Australian
Red Cross and the International Federation of the Red Cross and Red Crescent
Societies (IFRC). It is in the process of expanding its level of involvement in bloodrelated activities.

47

Challenges and the way forward
Though the countries that form the SEA Region have a high prevalence of
haemoglobinopathies (2.5–15%), each country is unique with its own prevalence and
distribution of these diseases. Even within a single country, the prevalence of
haemoglobinopathies varies depending on the ethnicity of the population in the region.
While some countries have well documented prevalence data that are publicly
available, other countries lack unified data for the entire country and have only
fragmented regional data. In many countries, there is lack of available mutational data
that would help both in carrier screening and in establishing a programme of prenatal
diagnosis in some societies. There are several reasons for this including the absence
of a unified action plan for the country for control of haemoglobinopathies such as a
national

thalassaemia

control

programme

and

lack

of

recognition

of

haemoglobinopathies as a major health problem especially when malnutrition,
vaccine-preventable diseases and diarrhoeal diseases are widely prevalent. In
addition, uniform guidelines for management of these disorders are not available.
Regular blood transfusions play a major role in the management of a child with
thalassaemia/haemoglobinopathy. The national blood services need to play an
important role in ensuring that regular blood transfusions are given in a timely manner
to the affected child. Some countries have a unified centralized blood collection
programme (e.g. Sri Lanka). This may not be possible in certain other countries either
because of size (e.g. India) or geographical constraints (e.g. Bhutan, Nepal, Maldives).
Inadequate availability of VNRBD, the lack of uniform testing practices for TTI and the
absence of cost-free blood availability for these patients are compounding factors.
These factors contribute to inadequate and delayed transfusions leading to poor
growth and a poor QoL in affected individuals.

The question arises how the MoH in each country along with WHO and other
international stakeholders can help correct this situation? The solutions needed for
each country may be unique depending upon their national strengths and
weaknesses. Nevertheless, there are guiding principles that should govern the
implementation

of

public

health

interventions

for

management

of

haemoglobinopathies. A combination of implementable structural and functional
strategies should help in improving the detection and management of patients with
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haemoglobinopathies. In that context, the following recommendations may be helpful
to national decision-makers and international stakeholders.

Establishment of national programmes for haemoglobinopathies
1. Recognition of haemoglobinopathies as a major health problem: It is important
for each MoH to recognize haemoglobinopathies as a major health problem
because recognition at the national level will lead to allocation of funds to help
manage this disease.
2. Development of a national registry: It is important for each country to develop
a unified national registry for haemoglobinopathies such as cancer
registries/databases that are developed. It may be a single registry where data
are submitted directly or there could be regional registries that collect the data
and

feed

regularly

to

the

national

registry.

All

patients

with

haemoglobinopathies should be documented in this registry especially if they
need government subsidies for their treatment.
3. Development of a national haemoglobinopathy diagnostic and prevention
programme: Every country should develop, implement and mandate
participation in its own haemoglobinopathy diagnostic and prevention
programmes. This would entail planning studies to understand the patterns of
mutation in various regions in the country and then setting up a comprehensive
carrier detection programme. Each country should explore the possibility of
starting programmes for genetic counselling and prenatal diagnosis if permitted
by the society.
4. Development

of

a

national

haemoglobinopathy

clinical

management

programme: Every country should develop its own national guidelines on
diagnosis and clinical management of haemoglobinopathies in conformance
with internationally recognized guidelines. There should be an inbuilt
mechanism to do periodical audits of clinical practices. In addition, mechanisms
for education and training of relevant health workers should be encouraged at
the regional and national levels.
5. Development of specialized patient care centres: Multiple specialized patient
care centres need to be established in areas where haemoglobinopathies are
prevalent. These centres should take on the primary role of delivering
appropriate management practices for children with thalassaemia and other
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haemoglobinopathies, which include the provision of regular blood transfusion,
monitoring of iron status, provision of iron-chelation therapy and facilitation of
carrier testing. To facilitate patient access, each centre should cover a radius
no greater than 50–100 km. If the centre is situated at the periphery, it should
be suitably linked to a nearby blood bank/hospital to provide transfusion.
6. Establishing national blood services
The differences in geographical extent, population density and availability of
resources make it challenging to implement uniform protocols for blood
services. The general principles that may be adopted are:
a. To establish nationalized blood services: This could be either at the country
level in smaller nations or at a regional level in larger nations.
b. To have uniform policy standards and quality practices starting from donor
screening to testing for all blood banks both in the public and private sectors.
c. To develop national guidelines on optimal transfusion therapy for patients with
thalassaemia major.
d. To ensure safety and quality of blood components by implementing sensitive
TTI screening tests and provision of leukodepleted blood products to prevent
allo-immunization.
e. To raise public awareness about blood donation and to work towards 100%
VNRBD and eliminate the role of paid donors.
f. To make available legally cost-free blood for individuals with thalassaemia: This
means that a family with a child affected by thalassaemia or any other clinically
significant haemoglobinopathy should be able to obtain free blood for their
regular transfusions at no cost to the family and without the need for the family
to donate. This requires appropriate allocation of funds from the government to
blood centres.
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International collaboration
The countries of the SEA Region operate under significant constraints of
infrastructure and resources, which limit their ability to recognize and respond to the
challenges posed by the prevalence of haemoglobinopathies. International
collaboration will help promote progress in this area of public health.
1. There is a specific need to promote intercountry collaboration for training and
capacity building, and to promote transfer of affordable technologies to developing
countries. National MoHs should seek to develop partnerships with countries that
are

more

advanced

in

diagnosis

and

management

of

patients

with

haemoglobinopathies.
2. International societies and associations exist that provide advocacy and expert
advice on identification and care of patients with haemoglobinopathies (e.g.
Thalassaemia International Federation, Global Sickle Cell Disease Network).
National MoHs should open communication with such organizations for knowledge
transfer and technical support that they can provide to programme development
for haemoglobinopathies.
3. WHO is uniquely positioned to promote international collaboration and to mobilize
technical

support

for

national

programme

development

to

address

haemoglobinopathies including thalassaemia. MoHs should reach out to WHO with
requests for technical support to advance their blood services and to facilitate
development, implementation and monitoring of national programmes for
haemoglobinopathies. This could include assistance with setting up genetic
testing, establishment and running of patient registries, and formulation of clinical
guidelines. Through their participation in the World Health Assembly, MoHs could
seek a resolution for WHO to declare one year as the “Year of the thalassaemic
child” to provide global impetus towards addressing the identified unmet needs.
4. World Thalassaemia Day is observed on 8 May every year. The theme for 2021
World Thalassaemia Day was “Addressing health inequalities across the global
thalassaemia community”. The theme for 2020 was “The dawning of a new era for
thalassaemia: time for a global effort to make novel therapies accessible and
affordable to patients” and in 2019, it was “Universal access to quality thalassaemia
health-care services: building bridges with and for patient”. All these reflect the
ongoing global efforts to improve the care of individuals with thalassaemia.
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Table 3. Summary of thalassaemia and blood services in countries of the SEA Region
Country

No. of

Annual births

No. of red cells

Under-5 mortality

thalassaemia

with

available per 100 000

rates (2019)

cases

thalassaemia

population

(per 1000 live

Prevalence

Mutation

National

Thalassaemia

Centralized

Free

Voluntary

Transfusion

data

data

registry

centres

blood service

blood

donors

guidelines

available

available

available

births)

60–70 000

9100

482

30.75

Yes

Yes

Nil

+/-

No

No

+/-

Yes

Very low

Low

713

28.49

–

–

–

–

Yes

Yes

+/-

Yes

NA

NA

NA

17.3

–

–

–

–

Yes

?

?

?Yes

India

150 000

12 500

769

34.27

Yes

Yes

Nil

+/-

No

Yes

+/-

Yes

Indonesia

10 530

2500

1118

23.9

Yes

Yes

Nil

+/-

Yes

+/-

+/-

Yes

Maldives

12 652

28

2759

7.62

Yes

Yes

Yes

+/-

Yes

Yes

+/-

Yes

Myanmar

4000

2500
(mainly HbE-β)

323

44.7

Yes

Yes

Nil

+/-

Yes

No

+/-

No

Nepal

300

120
(mainly HbE-β)

790

30.8

Yes

Yes

Nil

+/-

Yes

No

+

+/-

Sri Lanka

2000

45–55

1924

7.11

Yes

Yes

Nil

+/-

Yes

No

+

Yes

Thailand

98 460

4000
(mainly HbE-β)

3315

9

Yes

Yes

Nil

–

Yes

No

Yes

Yes

NA

25

256

44.22

–

–

–

–

Yes

No

+/-

Yes

Bangladesh
Bhutan
DPR Korea

Timor-Leste
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Table 4. Key metrics of SEAR countries
Bangladesh
Number/%

Bhutan

DPR
Korea

India

Indonesia

Maldives

Myanmar

Nepal

Sri
Lanka

Thailand

TimorLeste

Total population in millions [2020]

164.8

0.77

25.7

1380

273

0.54

54

29.1

21.4

69

1.3

Population aged 0–14 in 2020 (%)

26.8

24.9

19.8

26.2

25.9

19.6

25.5

28.8

23.7

16.6

36.8

14 111

62

176

119 707

23 569

32

4659

2798

1571

3339

193

16.7

15.8

13.5

17.59

16.8

12.1

16.8

18.4

14.5

9.5

27.9

Estimated births (in 000) (in 2020–2025)
Crude birth rate (per 1000)
(2020–2025)

World Bank category [2020]

Estimated number of children with thalassaemia
major [β-thalassemia and HbE-β thalassaemia]

Annual blood donations (2017)

Red blood cell units available per 100 000 (10)
Under 5 mortality rate [deaths per 1000 live births]
2019

Lower

Lower

middle

middle

income

income

60 – 70 000
(11)

756 061
(10,12)

No data
but very
low

6825

Low
income

No data
available

130 000
(19)

Lower

Upper

Upper

Lower

Lower

Lower

Upper

Lower

middle

middle

middle

middle

middle

middle

middle

middle

income

income

income

income

income

income

income

income

150 000

10 531

861

4000

2000

98 460

No data

11 100 000

2 886 233

12652

170 743
(10)

250–
300

236 799

450 640

2 341 571
(10)

3291

482

713

17.3

769

1118

2759

323

790

1924

3315

256

30.75

28.49

17.3

34.27

23.9

7.62

44.7

30.8

7.11

9

44.22
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Disorders of haemoglobin are one of the most common monogenic disorders prevalent

across the world. While sickle cell disorders are more prevalent worldwide, the thalassaemic syndromes including α and β-thalassaemia and haemoglobin-E disease are

associated with high prevalence rates in the countries of the WHO SEA Region. This desk
review was performed using data from thalassaemia societies, the nodal authorities

dealing with blood product support, data published in the literature and data from
WHO. Member states may find it useful to leverage the information contained herein to

develop national action plans to address this problem in all possible ways including
access to sufficient and secure blood and blood products, and safe transfusion services,
as a vital part of achieving universal health coverage.
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